Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine
Abstract Eptinezumab is a humanized mAb that targets calcitonin gene‐related peptide and is under regulatory review for the prevention of episodic and chronic migraine (EM, CM). It is important to determine whether exposures achieved with intravenous (IV) administration of eptinezumab achieve desire...
Saved in:
Main Authors: | Brian Baker (Author), Barbara Schaeffler (Author), Martin Beliveau (Author), Igor Rubets (Author), Susan Pederson (Author), MyMy Trinh (Author), Jeff Smith (Author), John Latham (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies
by: Brian Baker, et al.
Published: (2022) -
Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
by: Damiana Scuteri, et al.
Published: (2021) -
Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
by: Altamura C, et al.
Published: (2023) -
Corrigendum to "Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies"
Published: (2024) -
Episodic Mydriasis as Migraine Equivalent
by: J Gordon Millichap
Published: (1991)